ArticleJournal of Alzheimer's disease : JAD2020
Pharmaceutical Treatment for Alzheimer's Disease and Related Dementias: Utilization and Disparities.
Article in Journal of Alzheimer's disease : JAD, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 90 citations in OpenAlex.
- Article
- Plant-mediated green nanoparticles: combining nanometal and biometabolite potential for Alzheimer's treatment.Biomedical engineering online · 2026Review
- Value-based prices of emerging disease-modifying therapies for Alzheimer's disease in 174 countries: a cost-effectiveness and threshold analysis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Stratification of Alzheimer's disease patients using knowledge-guided unsupervised latent factor clustering with electronic health record data.Communications medicine · 2026Article
- Cholinesterase inhibitors for patients with dementia: Patterns of prescribing and disparities in treatment.Journal of Alzheimer's disease : JAD · 2026Article
- Versatility of Transcranial Magnetic Stimulation: A Review of Diagnostic and Therapeutic Applications.Brain sciences · 2026Review
- Treatment patterns of symptomatic treatments for Alzheimer's disease and related dementias.BMC geriatrics · 2025Article
- Regional disparities of antidementia drug treatment in Germany: what can we learn for the new generation of Alzheimer's therapies.Alzheimer's research & therapy · 2025Article
- Can Telehealth Improve Access to Amyloid-Targeting Therapies for Veterans Living With Alzheimer Disease?Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2025Article
- The National Dementia Workforce Study: Perspective From the National Institute on Aging.Journal of the American Geriatrics Society · 2025Article
- Using machine learning and electronic health record (EHR) data for the early prediction of Alzheimer's Disease and Related Dementias.The journal of prevention of Alzheimer's disease · 2025Article
- Trends in Co-morbid Dementia and Chronic Kidney Disease.Journal of general internal medicine · 2025Article
- Participation in clinical research among racial and ethnic minority Medicare beneficiaries: Evidence from the IDEAS study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Advancing Alzheimer's Therapy: Computational strategies and treatment innovations.IBRO neuroscience reports · 2025Review
- Cost-effectiveness analysis of aducanumab versus placebo for patients with mild cognitive impairment and mild Alzheimer's disease.BMJ open · 2025Article
- Dementia diagnosis and prescription of antidementia drugs: An analysis of German claims data (2006-2016).Journal of Alzheimer's disease : JAD · 2025Article
- Dementia Medications and Their Association with Pain Medication Use in Medicare Beneficiaries with Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Chronic Pain.Drugs & aging · 2025Article
- Using Under-Represented Subgroup Fine Tuning to Improve Fairness for Disease Prediction.Biomedical engineering systems and technologies, international joint conference, BIOSTEC ... revised selected papers. BIOSTEC (Conference) · 2025Article
- Policy and Organizational Factors that Affect the Utilization of Health Services for Alzheimer's Disease Among the Latino Community - The Primary Care Provider Perspective.Journal of the National Hispanic Medical Association · 2025Article
- Neuraminidase as a novel therapeutic management strategy for Alzheimer's disease: evidenced through molecular docking, molecular dynamic simulation and gene expression analysis.Frontiers in chemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundFour prescription drugs (donepezil, galantamine, memantine, and rivastigmine) are approved by the US FDA to treat symptoms of Alzheimer's disease (AD). Even modest effectiveness could potentially reduce the population-level burden of AD and related dementias (ADRD), especially for women and racial/ethnic minorities who have higher incidence of ADRD.
objectiveDescribe the prevalence of antidementia drug use and timing of initiation relative to ADRD diagnosis among a nationally representative group of older Americans, and if there are disparities in prevalence and timing by sex and race/ethnicity.
methodsDescriptive analyses and logistic regressions of Medicare claims (2008-2016) for beneficiaries who had an ADRD or dementia-related symptom diagnosis, or use of an FDA approved drug for AD. We investigate prevalence of use and timing of treatment initiation relative to ADRD diagnosis across time and beneficiary characteristics (age, sex, race/ethnicity, socioeconomic status, comorbidities).
resultsAmong persons diagnosed with ADRD or related symptoms, 33.3% used an approved drug over the study period. Odds of use was higher among Whites than non-Whites. Among ADRD drug users, 40% initiated use within 6 months of the initial ADRD or related symptoms diagnosis, and 16% initiated prior to a diagnosis. We observed disparities by race/ethnicity: 28% of Asians, 24% of Hispanics, 16% of Blacks, and 15% of Whites initiated prior to diagnosis.
conclusionsThe use of antidementia drugs is relatively low and varies widely by race/ethnicity. Heterogeneity in timing of initiation and use may affect health and cost outcomes, but these effects merit further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.